| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
Cell lines | LPS-stimulated THP-1 cells |
Preparation Method | THP-1 cells were cultured with LPS in the presence or absence of antibiotics (Sitafloxacin) for 4 h. Following the incubation, supernatants were collected. |
Reaction Conditions | 1-50 μg/mL Sitafloxacin for 4h |
Applications | Sitafloxacin significantly reduced the concentration of TNFα in the supernatants of LPS-stimulated THP-1 cells than other quinolone antibiotics did; Sitafloxacin also reduced the levels of IL-8, IP-10, MCP-1, MIP-1α and MIP-1β. |
Animal models | Six-week-old male, ddY, specific-pathogen-free mice (body weight 16-20 g) |
Preparation Method | From 24 h after infection, antibiotics were administered orally twice a day to the Sitafloxacin and CPFX treatment groups for 3 days.Each single dose was 10 mg/kg |
Dosage form | 10 mg/kg Sitafloxacin twice a day for 3 days |
Applications | In Sitafloxacin-treated mice, H. influenzae was decreased by 3 days after starting oral administration of Sitafloxacin. |
| 产品描述 | Sitafloxacin is a new fluoroquinolone offering a broader spectrum , as a broad-spectrum antimicrobial agent[2],has more potent activity against Gram-positive, Gramnegative and atypical pathogens than other quinolones such as ofloxacin, CPFX and sparfloxacin[7,8]. Sitafloxacin suppressed TNFα production more strongly than the other quinolone antibiotics. It did not suppress the signaling pathways that produced TNFα but increased phosphorylated ERK. Sitafloxacin inhibited the extracellular release of TNFα[5,6].TACE specifically cleaves pro-TNFα to release TNFα from cell. Sitafloxacin reduced the phosphorylation and activity of TACE[1]. Sitafloxacin is effective against pneumococcal infections, and incidence of drug-resistant mutants is low in vitro conditions[3]. Sitafloxacin was effective against Haemophilus influenzae pneumonia in a murine model. In Sitafloxacin-treated mice, H. influenzae was decreased by 3 days after starting oral administration of Sitafloxacin, total cell counts and neutrophil counts in BALF were considerably decreased, and histopathologically inflammatory changes were greatly improved with Sitafloxacin treatment[4]. Sitafloxacin can achieve a higher tissue concentration than CPFX[9]. Besides, Sitafloxacin monotherapy might be effective against low-risk FN in lung cancer patients[10]. References: |
m.cnreagent.com